|Affimed NV, of Heidelberg, Germany||AFM-13||CD30- and CD16A-binding innate cell engager||T-cell lymphoma||FDA granted orphan drug designation|
|Applied Therapeutics Inc., of New York||AT-001||Aldose reductase inhibitor||COVID-19||IND opened with FDA for multiple investigator-initiated studies|
|Celularity Inc., of Warren, N.J.||CYNK-001||Placenta-derived natural killer cell therapy||COVID-19||FDA cleared the IND for a phase I/II trial|
|Fera Pharmaceuticals LLC, of New York, and Nicox SA, of Sophia Antipolis, France||Naproxcinod||Cyclooxygenase-inhibiting, nitric oxide-donating naproxen||Sickle cell disease||Applied for orphan drug designation with the FDA|
|Pfizer Inc., of New York||Ruxience (rituximab)||Biosimilar to Mabthera||Non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris||Approved by the European Commission|
|Pharmamar SA, of Madrid||Aplidin (plitidepsin)||Cyclodepsipeptide||COVID-19 pneumonia||Submitted trial protocol for the Aplicov study to the Spanish Medicines and Healthcare Products Agency|
|Seattle Genetics Inc., of Bothell, Wash.||Padcev (enfortumab vedotin-ejfv)||Antibody-drug conjugate targeting Nectin-4||Unresectable locally advanced or metastatic urothelial cancer||FDA said data from cohort K of the EV-103/Keynote-869 study could serve as a pivotal study testing drug in patients unable to receive cisplatin-based chemotherapy in the first-line setting|
For more information about individual companies and/or products, see Cortellis.